Fc fusion proteins represent a groundbreaking class of biopharmaceuticals that leverage the natural mechanism of the human antibody. By fusing a therapeutic protein, such as a cytokine, receptor, or enzyme, to the fragment crystallizable (Fc) region of an immunoglobulin G (IgG) antibody, scientists can dramatically extend the therapeutic agent's circulating half-life. This extension is...